American Association for Cancer Research
10780432ccr193467-sup-231103_2_supp_5998272_q3jfpb.docx (17.86 kB)

Supplementary Methods from Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers

Download (17.86 kB)
journal contribution
posted on 2023-03-31, 22:32 authored by Aparna R. Parikh, Amikasra Mojtahed, Jaime L. Schneider, Katie Kanter, Emily E. Van Seventer, Isobel J. Fetter, Ashraf Thabet, Madeleine G. Fish, Bezaye Teshome, Kathryn Fosbenner, Brandon Nadres, Heather A. Shahzade, Jill N. Allen, Lawrence S. Blaszkowsky, David P. Ryan, Bruce Giantonio, Lipika Goyal, Ryan D. Nipp, Eric Roeland, Colin D. Weekes, Jennifer Y. Wo, Andrew X. Zhu, Dora Dias-Santagata, A. John Iafrate, Jochen K. Lennerz, Theodore S. Hong, Giulia Siravegna, Nora Horick, Jeffrey W. Clark, Ryan B. Corcoran

Supplementary Methods






ctDNA offers a promising, noninvasive approach to monitor therapeutic efficacy in real-time. We explored whether the quantitative percent change in ctDNA early after therapy initiation can predict treatment response and progression-free survival (PFS) in patients with metastatic gastrointestinal cancer. A total of 138 patients with metastatic gastrointestinal cancers and tumor profiling by next-generation sequencing had serial blood draws pretreatment and at scheduled intervals during therapy. ctDNA was assessed using individualized droplet digital PCR measuring the mutant allele fraction in plasma of mutations identified in tumor biopsies. ctDNA changes were correlated with tumor markers and radiographic response. A total of 138 patients enrolled. A total of 101 patients were evaluable for ctDNA and 68 for tumor markers at 4 weeks. Percent change of ctDNA by 4 weeks predicted partial response (PR, P < 0.0001) and clinical benefit [CB: PR and stable disease (SD), P < 0.0001]. ctDNA decreased by 98% (median) and >30% for all PR patients. ctDNA change at 8 weeks, but not 2 weeks, also predicted CB (P < 0.0001). Four-week change in tumor markers also predicted response (P = 0.0026) and CB (P = 0.022). However, at a clinically relevant specificity threshold of 90%, 4-week ctDNA change more effectively predicted CB versus tumor markers, with a sensitivity of 60% versus 24%, respectively (P = 0.0109). Patients whose 4-week ctDNA decreased beyond this threshold (≥30% decrease) had a median PFS of 175 days versus 59.5 days (HR, 3.29; 95% CI, 1.55–7.00; P < 0.0001). Serial ctDNA monitoring may provide early indication of response to systemic therapy in patients with metastatic gastrointestinal cancer prior to radiographic assessments and may outperform standard tumor markers, warranting further evaluation.

Usage metrics

    Clinical Cancer Research



    Ref. manager